Third Harmonic Bio Inc. (THRD) NASDAQ
$13.97 (0.26) (-1.83%)
Market Cap: $582.71M
As of 05/17/24 01:30 PM EDT. Market open.
Third Harmonic Bio Inc. (THRD)
NASDAQ
$13.97
(0.26) (-1.83%)
Market Cap: $582.71M
As of 05/17/24 01:30 PM EDT. Market open.
Add to Portfolio
third harmonic bio is a clinical-stage company developing a highly selective, oral kit inhibitor for treatment of severe allergy and inflammation. kit is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Full Time Employees
26
URL
Address
.
PRICE CHART FOR THIRD HARMONIC BIO INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$14.23
Previous Close
$14.23
Days Range
$13.11 - $14.23
52 week range
$4.51 - $14.23
Volume
19,546
Avg. Volume (30 days)
147,887
Market Cap
$582.71M
Dividend Yield
-
P/E
-
Shares Outstanding
40,949,463
Open
$14.23
Previous Close
$14.23
Days Range
$13.11 - $14.23
52 week range
$4.51 - $14.23
Volume
19,546
Avg. Volume (30 days)
147,887
Market Cap
$582.71M
Dividend Yield
-
P/E
-
Shares Outstanding
40,949,463
FINANCIAL STATEMENTS FOR THIRD HARMONIC BIO INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR THIRD HARMONIC BIO INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Holles Natalie C. | CEO | May 09, 2024 | Option Exercise | $4.20 | 20,222 | 84,932 | 1,239,058 | May 10, 2024, 04:04 PM |
| Holles Natalie C. | CEO | May 09, 2024 | Sale | $12.18 | 20,222 | 246,300 | 1,218,836 | May 10, 2024, 04:04 PM |
| Holles Natalie C. | CEO | Apr 11, 2024 | Option Exercise | $4.20 | 13,558 | 56,944 | 1,232,394 | Apr 15, 2024, 04:14 PM |
| Holles Natalie C. | CEO | Apr 11, 2024 | Sale | $12.19 | 13,558 | 165,214 | 1,218,836 | Apr 15, 2024, 04:14 PM |
| Person Julie | CHIEF ADMINISTRATIVE OFFICER | Apr 04, 2024 | Option Exercise | $4.20 | 1,107 | 4,649 | 1,107 | Apr 08, 2024, 05:21 PM |
| Person Julie | CHIEF ADMINISTRATIVE OFFICER | Apr 04, 2024 | Sale | $10.00 | 1,107 | 11,070 | 0 | Apr 08, 2024, 05:21 PM |
| Person Julie | Chief Administrative Officer | Dec 05, 2023 | Option Exercise | $4.20 | 12,863 | 54,025 | 12,863 | Dec 07, 2023, 04:04 PM |
| Person Julie | Chief Administrative Officer | Dec 05, 2023 | Sale | $10.30 | 12,863 | 132,484 | 0 | Dec 07, 2023, 04:04 PM |
| Conner Edward R. | Chief Medical Officer | Dec 05, 2023 | Option Exercise | $4.20 | 4,790 | 20,118 | 4,790 | Dec 07, 2023, 04:03 PM |
| Conner Edward R. | Chief Medical Officer | Dec 05, 2023 | Sale | $10.03 | 4,790 | 48,062 | 0 | Dec 07, 2023, 04:03 PM |
| BVF PARTNERS L P/IL | 10% Owner | Dec 20, 2022 | Buy | $4.11 | 214,063 | 879,499 | 2,332,638 | Dec 22, 2022, 06:49 PM |
| ORBIMED ADVISORS LLC | Director | Sep 19, 2022 | Buy | $17.00 | 300,000 | 5,100,000 | 5,779,071 | Sep 21, 2022, 06:00 PM |
| Bonita David P | Director | Sep 19, 2022 | Buy | $17.00 | 300,000 | 5,100,000 | 5,779,071 | Sep 21, 2022, 05:59 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Sep 19, 2022 | Buy | $17.00 | 300,000 | 5,100,000 | 10,313,763 | Sep 19, 2022, 04:51 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Holles Natalie C. | CEO | 05/09/2024 | 84,932 |
| Holles Natalie C. | CEO | 05/09/2024 | 246,300 |
| Holles Natalie C. | CEO | 04/11/2024 | 56,944 |
| Holles Natalie C. | CEO | 04/11/2024 | 165,214 |
| Person Julie | CHIEF ADMINISTRATIVE OFFICER | 04/04/2024 | 4,649 |
| Person Julie | CHIEF ADMINISTRATIVE OFFICER | 04/04/2024 | 11,070 |
| Person Julie | Chief Administrative Officer | 12/05/2023 | 54,025 |
| Person Julie | Chief Administrative Officer | 12/05/2023 | 132,484 |
| Conner Edward R. | Chief Medical Officer | 12/05/2023 | 20,118 |
| Conner Edward R. | Chief Medical Officer | 12/05/2023 | 48,062 |
| BVF PARTNERS L P/IL | 10% Owner | 12/20/2022 | 879,499 |
| ORBIMED ADVISORS LLC | Director | 09/19/2022 | 5,100,000 |
| Bonita David P | Director | 09/19/2022 | 5,100,000 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 09/19/2022 | 5,100,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN THIRD HARMONIC BIO INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 5,779,071 | 1% | No change | Other |
| RA CAPITAL MANAGEMENT, L.P. | 2,033,056 | 0.25% | No change | Other |
| BLACKROCK INC. | 1,362,292 | 0.0003% | -1.94% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 400,068 | 0.00035% | -0.16% | Other |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 152,027 | 0.00345% | Exited | Other |
| RENAISSANCE TECHNOLOGIES LLC | 68,300 | 0.00101% | 425.38% | Other |
| OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) | 48,403 | 0.03% | -25.19% | Value |
| D. E. SHAW & CO., INC. | 28,974 | 0.00023% | 8.27% | Other |
CHANGE IN SHARES OUTSTANDING FOR THIRD HARMONIC BIO INC
STOCK BUYBACKS FOR THIRD HARMONIC BIO INC
Period of Report: 03/31/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
12/31/2023
0.84%
1Q
09/30/2023
1.32%
2Q
06/30/2023
1.62%
3Q
BUYBACK ANNOUNCEMENT(S) FOR THIRD HARMONIC BIO INC
LOADING...